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ARTICLE
Site-specific incorporation of citrulline into proteins
in mammalian cells
Santanu Mondal1,3, Shu Wang2,3, Yunan Zheng2, Sudeshna Sen1, Abhishek Chatterjee 2✉ &
Paul R. Thompson 1✉
Citrullination is a post-translational modification (PTM) of arginine that is crucial for several
physiological processes, including gene regulation and neutrophil extracellular trap formation.
Despite recent advances, studies of protein citrullination remain challenging due to the dif-
ficulty of accessing proteins homogeneously citrullinated at a specific site. Herein, we report a
technology that enables the site-specific incorporation of citrulline (Cit) into proteins in
mammalian cells. This approach exploits an engineered E. coli-derived leucyl tRNA
synthetase-tRNA pair that incorporates a photocaged-citrulline (SM60) into proteins in
response to a nonsense codon. Subsequently, SM60 is readily converted to Cit with light
in vitro and in living cells. To demonstrate the utility of the method, we biochemically
characterize the effect of incorporating Cit at two known autocitrullination sites in Protein
Arginine Deiminase 4 (PAD4, R372 and R374) and show that the R372Cit and R374Cit
mutants are 181- and 9-fold less active than the wild-type enzyme. This technology possesses
the potential to decipher the biology of citrullination.
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C itrullination is a post-translational modification (PTM)that involves the hydrolysis of the positively chargedguanidium group on arginine to generate a neutral urea
(Fig. 1a)1. Citrullination plays crucial roles in many physiological
processes, including the epigenetic regulation of gene transcrip-
tion, neutrophil extracellular trap (NET) formation or NETosis,
and maintaining pluripotency1–7. Citrullination is catalyzed
by the protein arginine deiminases (PADs) (Fig. 1a), a group of
four catalytically active cysteine hydrolases (PAD1–4)8. PADs are
Ca2+-dependent enzymes and the presence of calcium increases
PAD activity by >10,000-fold. Calcium-binding leads to dramatic
conformational rearrangements, particularly of the nucleophilic
cysteine (C645 in PAD1, 4; C647 in PAD2; C646 in PAD3) to
form a catalytically competent active site9.
Aberrant protein citrullination is a hallmark of multiple
autoimmune disorders, including rheumatoid arthritis (RA),
Fig. 1 SM60, a photocaged-citrulline and its conversion to citrulline with 365 nm UV light. a Conversion of peptidyl-arginine to peptidyl-citrulline by the
PADs. b Chemical structures of SM60 and SM70. c Schematic representation of the incorporation of SM60 into proteins by an engineered LeuRS-tRNALeu
pair and subsequent conversion to citrulline. d Decaging of SM60 to citrulline with 365 nm UV irradiation. Left and right panels indicate the HPLC and ion
chromatograms, showing the disappearance of SM60 and the formation of citrulline (Cit), respectively, with increasing UV exposure. Quantitative analyses
of decaging and Cit formation are shown in the insets. n= 2 independent experiments, data are presented as mean value ± SD. Assay mixture: 1 mM SM60,
2 mM DTT, phosphate-buffered saline pH 7.4. Source data are provided as a Source Data file.
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multiple sclerosis (MS), ulcerative colitis (UC), and lupus, as well
as several neurodegenerative diseases and cancer. Of note, mul-
tiple pan- and isozyme-selective PAD inhibitors are known and
these inhibitors show efficacy in animal models of RA, UC, MS,
lupus, and sepsis1,8,10–12. The contribution of protein hyperci-
trullination to the pathology of various diseases has been further
established using the phenylglyoxal (PG)-based citrulline (Cit)-
specific probes, Rhodamine-PG (Rh-PG) and Biotin-PG1,8. For
example, Rh-PG enabled visualization of extensive citrullination
of serum proteins and a marked decrease upon treatment with
pan-PAD inhibitor, Cl-amidine, in a mouse model of UC13.
Using Biotin-PG and a chemoproteomic platform, we also
identified various classes of novel citrullinated proteins, including
serine protease inhibitors (SERPINs), serine proteases, transport
proteins, and complement system components along with known
citrullinated proteins (e.g., vimentin, enolase, keratin, and fibrin)
in the serum, synovial fluid, and synovial tissue of RA patients14.
Although the list of citrullinated proteins is ever-expanding, the
effect of citrullination on the structure and activity of a given
protein remains poorly understood.
The most commonly used strategy for generating a citrulli-
nated protein involves its treatment with a PAD. However, this
leads to citrullination at all sites that are available in vitro, which
may not fully recapitulate the situation in vivo. Moreover, the
degree of modification at each site is frequently partial, leading to
a complex heterogeneous mixture14–16. Clearly, this strategy fails
to provide information on the effect of individual citrullination
events, underscoring the need for a method to site-specifically
incorporate Cit into proteins.
Although Gln mutations have been used as surrogates for Cit17,
Gln is smaller and does not accurately mimic the H-bonding patterns
afforded by Cit. The in vitro translation systems or post-translational
mutagenesis approaches that have been used to incorporate Cit are
limited by their cumbersome nature, the need for specialized
equipment, and for the latter approach, the need to incorporate a
dehydroalanine at the site of modification, which is itself challenging
and generates a mixture of D- and L-stereoisomers18,19. In addition,
these strategies preclude the expression of site-specifically citrulli-
nated proteins in living cells, and therefore, are ineffective for inter-
preting the downstream implications of this PTM. By contrast,
Genetic Code Expansion (GCE) technologies enable the site-specific
incorporation of unnatural amino acids (UAAs) into proteins using
engineered aminoacyl-transfer RNA synthetase (aaRS)–tRNA
pairs20–24. This technology has been used to genetically encode many
important PTMs, enabling the expression of homogeneously mod-
ified protein at desired sites in living cells25–28. However, genetically
encoding Cit using this technology has remained elusive so far.
In this work, we report the facile site-specific incorporation of Cit
into proteins in mammalian cells using an Escherichia coli-derived
engineered leucyl-tRNA synthetase (EcLeuRS)–tRNACUAEcLeu pair.
This pair, in response to a nonsense codon (UAG), charges a
photocaged-Cit, SM60 (Fig. 1b, c), into proteins expressed in
HEK293T or EXPI293F cells. Subsequently, the photocage is
removed with 365 nm ultraviolet (UV) to generate Cit in vitro or in
living cells (Fig. 1c). To demonstrate proof of concept, we incor-
porate Cit at two well-known autocitrullination sites, R372 and
R374, in PAD4 and elucidate how these modifications impact
enzyme activity.
Results
Development of SM60: a photocaged-Cit. Envisioning that it
may be challenging to develop an engineered aaRS that would
selectively charge Cit, while discriminating against a nearly iso-
structural arginine, we hypothesized that these challenges could
be overcome through a caging strategy. As such, we designed a
photocaged-Cit (SM60, comprising an o-nitrobenzyl photocage
on the Cit side chain), which is structurally distinct from the 20
canonical amino acids, but can be efficiently converted to Cit
post-translationally (Fig. 1b, d). SM60 was synthesized over two
steps from L-ornithine, and was characterized by 1H, 13C nuclear
magnetic resonance (NMR) spectroscopy and mass spectrometry
(MS) (Supplementary Figs. 1 and 2a). Using liquid
chromatography-MS (LC-MS), we found that SM60 can be
quantitatively converted to Cit in phosphate-buffered saline
(PBS) supplemented with dithiothreitol (DTT) using 365 nm UV
radiation for 5 min (Fig. 1d and Supplementary Fig. 3). The
quantitative conversion was further supported by 1H NMR ana-
lysis, which shows the rapid disappearance of the benzylic pro-
tons of SM60 at 4.5 p.p.m. with increasing UV exposure and by
the photodecaging of Fmoc-SM60 to Fmoc-Cit (Supplementary
Figs. 4 and 5). To further investigate the feasibility of decaging
SM60 on proteins, we synthesized an SM60-containing peptide,
SM70 (Fig. 1b and Supplementary Fig. 2b), that contains residues
363–372 of PAD4 with SM60 at the 372 position, a known
autocitrullination site (see below). Gratifyingly, SM70 also
undergoes photodecaging to form the Cit-containing peptide
(Supplementary Fig. 6), indicating that SM60 can be decaged in
the presence of other amino acids.
Genetically encoding SM60 in eukaryotes. Four different aaRS/
tRNA pairs have been successfully engineered for incorporating
UAAs in eukaryotic cells: bacteria-derived tyrosyl, tryptophanyl,
and leucyl pairs and the archaea-derived pyrrolysyl pair21–24,29,30.
The first two pairs are restricted to structural analogs of pheny-
lalanine and tryptophan, respectively, precluding their use to
genetically encode SM60. However, both the archaeal pyrrolysyl
(PylRS/tRNAPyl) and E. coli leucyl (EcLeuRS-tRNACUAEcLeu)
pairs have been engineered to charge UAAs structurally like
SM60. Engineered aaRSs often exhibit substrate polyspecificity,
that is, the ability to use several structurally analogous UAAs,
while discriminating against the canonical amino acids. This
property has provided a facile route to rapidly expand the
repertoire of genetically encoded UAAs without having to engi-
neer new aaRS mutants for each distinct substrate. To explore if
such a polyspecific aaRS can accept SM60 as a substrate, we
screened several existing PylRS and EcLeuRS mutants using an
EGFP-39-TAG expression assay in HEK293T cells in the pre-
sence of their cognate amber suppressor tRNA. This screen
identified an EcLeuRS mutant (M40I, Y499I, Y527A, and H529G
in the active site, and T252A in the editing domain)31, which
enabled the robust expression of the fluorescence reporter only
when SM60 was supplemented in the medium (Fig. 2a, b). Pur-
ification of the resulting full-length EGFP using a C-terminal
polyhistidine tag, followed by MS, showed a mass consistent with
the successful incorporation of SM60 (Fig. 2c, d). Furthermore,
UV irradiation of cells expressing EGFP-39-SM60 before lysis
followed by protein purification and MS analysis afforded a single
protein mass consistent with the complete deprotection and
incorporation of Cit at position 39 of EGFP (Fig. 2d). Notably,
SM60 is completely nontoxic (half-maximal effective concentra-
tion (EC50) > 10 mM) in HEK293T cells at the concentration used
for nonsense suppression, that is, 1 mM (Supplementary
Fig. 10A). Furthermore, a combination of SM60 and 365 nm UV
exhibits an EC50 of 4.5 ± 0.2 mM for the inhibition of cell pro-
liferation, indicating that the products of the photodecaging
reaction (nitrosobenzaldehyde and Cit) have negligible cytotoxi-
city at the working concentration (Supplementary Fig. 10A).
Site-specific incorporation of Cit in PAD4. Having established
our ability to site-specifically incorporate Cit into EGFP, we
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sought to exploit this technology to address the effect of auto-
citrullination on PAD4 activity. We focused on these studies
because the effect of autocitrullination on PAD4 activity has been
debated. While Andrade et al.32 reported that autocitrullination
negatively impacts PAD4 activity, we showed that auto-
citrullination has little to no impact on PAD4 activity17. Using a
Cit-specific fluorescent probe Rh-PG13, we confirmed that PAD4
autocitrullinates in the presence of Ca2+ in a time-dependent
manner (Fig. 3a). We and others have previously mapped several
autocitrullination sites in PAD4 (Supplementary Table 1 and
Supplementary Fig. 11)17,32. While most of these sites are on the
surface, the frequently observed R372 and R374 sites are present
in the active site. Notably, the guanidinium groups on these two
residues are only 3.5 Å from each other and the expected elec-
trostatic repulsions are delicately balanced by H-bonding and
salt-bridge interactions with D345. Moreover, R374 forms two H
bonds with the small-molecule substrate, BAA33. Therefore, we
expected that citrullination at these sites would significantly
impact enzyme activity. To evaluate this hypothesis, we incor-
porated Cit at positions 372 and 374 in PAD4. Wild-type (WT)
Fig. 2 Site-specific incorporation of SM60 in EGFP and subsequent conversion to citrulline in HEK293T cells. a EGFP-39-TAG reporter expression by
EcLeuRS-tRNACUAEcLeu pair in HEK293T cells in the presence of SM60 indicated by the fluorescence of EGFP. b Quantification of EGFP-39-TAG reporter
expression efficiency in the presence of an increasing concentration of SM60. n= 3 independent experiments, data are presented as mean value ± SD. The
solid circles represent data points for biologically independent replicates. Source data are provided as a Source Data file. c Coomassie stain of purified EGFP
containing SM60. Full gel is given in Supplementary Fig. 7. d Deconvoluted mass spectrum of EGFP before and after 365 nm UV irradiation (1 min),
indicating the presence of SM60 and citrulline, respectively, at position 39. Non-deconvoluted spectra are given in Supplementary Figs. 8 and 9.
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PAD4 and the 372 and 374 TAG mutants were separately cloned
into a pAcBac3 plasmid31,34, which also encodes the mutant
EcLeuRS and eight copies of the tRNACUAEcLeu. Subsequently,
these plasmids were transfected separately into HEK293T cells,
and the PAD4 protein or its mutants (after irradiation to remove
the photocage), were purified using a C-terminal polyhistidine
tag. While WT PAD4 expression was robust (10 µg/107 cells),
yields for the mutants were very low, indicating poor suppression
efficiency at these sites. The Chin group has recently reported a
mutant eukaryotic release factor (eRF1-E55D) that can enhance
TAG suppression efficiency in mammalian cells upon over-
expression35. To explore if this strategy can overcome the low
suppression efficiency at the target sites in PAD4, we cloned
eRF1-E55D mutant under a cytomegalovirus promoter in the
pIDTSMART vector. Indeed, co-transfection of this plasmid
significantly improved the efficiency of nonsense suppression and
Fig. 3 Autocitrullination of PAD4, incorporation of citrulline in PAD4 and implications thereof. a Chemical structure of Rh-PG and the fluorescence
labeling of autocitrullinated PAD4. The bands at 0min in the presence of calcium and at all the time points in the absence of calcium correspond to the
basal levels of autocitrullination during the expression and purification of PAD4 from E. coli. n= 2 independent experiments, data are presented as mean
value ± SD. b Expression of R372Cit PAD4 in the presence of engineered release factor, eRF1-E55D and SM60 in HEK293T cells, indicating the essential
role of eRF1-E55D for efficient TAG suppression. c Coomassie stains for WT, R372Cit and R374Cit PAD4, indicating their purity. d Michaelis–Menten
kinetics for WT, R372Cit, and R374Cit PAD4. n= 2 independent experiments, data are presented as mean value ± SD. e Western blot analysis of histone
H3 citrullination in live HEK293T cells by WT and R374Cit PAD4. The normalization procedure is given in the “Methods” section. n= 3 independent
experiments, data are presented as mean value ± SD. The samples derive from the same experiment and the blots were processed in parallel (see
Supplementary Fig. 20c for a detailed explanation). f Thermal shift profiles of WT and R374Cit PAD4. Western blot images are given in Supplementary Fig.
17. The table indicates the melting temperatures (Tm). n= 2 independent experiments, data are presented as mean value ± SD. The full gels corresponding
to panels (a), (b), and (e) are given in Supplementary Fig. 20. Source data for panels (a) and (d–f) are provided as a Source Data file.
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enabled the purification of the desired mutants (2–4 µg/107 cells,
Fig. 3b, c). Since the +0.98 Da mass change upon citrullination is
difficult to detect by intact MS analysis, we confirmed the
incorporation of Cit at the desired position by LC-MS/MS ana-
lysis of the peptides resulting from Lys-C/Glu-C digestion of
PAD4 (Supplementary Fig. 12, 13 and Supplementary Tables 2
and 3). Notably, we found that PAD4 expression does not cause
any cytotoxicity in the HEK293T cells (Supplementary Fig. 10B).
Using a similar procedure, we also expressed and purified WT
PAD4 and the R374Cit mutant from EXPI293F cells that grow in
suspension and are a highly scalable expression system (Supple-
mentary Fig. 14).
Activity of WT, R372Cit, R374Cit, and autocitrullinated
PAD4. We first ensured that the biochemical activity and calcium
dependence of WT PAD4 expressed from HEK293T cells
(PAD4Mam) and E. coli (PAD4Bac) are similar (Supplementary
Fig. 15a, b and Supplementary Table 4). Next, we determined
kinetic values for the R372Cit and R374Cit mutants. Notably,
both WT and the R374Cit mutant exhibited a time-dependent
increase in Cit production (Supplementary Fig. 15c). By contrast,
the R372Cit mutant produced only a negligible amount of Cit
after 90 min. Furthermore, the rate of Cit production, indicated
by the slope of the straight line, is significantly lower for the
R374Cit mutant than WT PAD4 (Supplementary Fig. 15c). In
agreement, the kcat/Km values of the R374Cit and R372Cit
mutants are 9- and 181-fold lower than that for WT PAD4
(Fig. 3d and Supplementary Table 4). These in vitro results led us
to investigate the activity of WT and R374Cit PAD4 in live cells.
Specifically, we overexpressed the two enzymes in HEK293T cells
and evaluated their ability to citrullinate histone H3. Treatment of
PAD4-overexpressing HEK293T cells with calcium and a calcium
ionophore, that is, ionomycin, followed by western blot analysis
indicated that WT PAD4 is six times more active than the
R374Cit mutant for the citrullination of histone H3, consistent
with the in vitro results (Fig. 3e).
Intrigued by these results, we sought to understand why the
activity of these Cit-containing mutants is lower than WT PAD4.
Kinetic studies indicate that the R374Cit mutant possesses a
similar Km, but a 10-fold lower kcat than WT PAD4 (Supple-
mentary Table 4), suggesting a slow conversion of substrate to
product. Furthermore, RFA, a PAD-targeted activity-based probe
that covalently modifies the active site cysteine, C64536,
fluorescently labeled only WT PAD4 when tested with both
purified enzymes and enzyme-containing cell lysates (Supple-
mentary Fig. 16). Based on these observations, we hypothesized
that citrullination may induce local conformational changes
within the active site, leading to very slow or no reaction between
C645 and the guanidium group of the substrate, Nα-benzoyl
arginine ethyl ester (BAEE), or the fluoroacetamidine warhead on
RFA. To investigate this possibility, we performed a thermal shift
assay in the presence of a PAD4-selective ligand, GSK199, which
binds to an allosteric pocket near the active site and H bonds to
both D473 and H47137. Using this assay, we found the
melting temperatures (Tm) of WT and R374Cit PAD4 to be
62.9 and 54.6 °C, respectively (Fig. 3f and Supplementary Fig. 17).
Despite having a lower Tm, the R374Cit mutant is as stable as WT
PAD4 at 37 °C (Supplementary Fig. 18). As expected, GSK199
increased the Tm of WT PAD4; however, it did not increase the
Tm of the R374Cit mutant (Fig. 3f). These results indicate that
GSK199 binds poorly to the R374Cit mutant, likely due to local
conformational changes around the active site. However, the
overall folding of the mutant is the same as WT since both the
WT and R374Cit proteins exhibit a similar ΔTm in the presence
of calcium (Fig. 3f).
Quantitative proteomics of PAD4 autocitrullination. As dis-
cussed earlier, conflicting reports indicated that autocitrullination
can either inactivate the enzyme or have no effect. Since our
present results suggest that autocitrullination should decrease
PAD4 activity, we regenerated autocitrullinated PAD4 by incu-
bating the enzyme in the presence of 10 mM CaCl2. Consistent
with our previous observations, autocitrullinated PAD4 exhibits
similar activity to control PAD4 (incubated in the absence of
CaCl2) (Supplementary Fig. 15d). The activity loss for both
autocitrullinated and control PAD4 in this experiment is likely
due to the oxidation of C645 over time. Given that auto-
citrullination does not decrease enzyme activity, but citrullination
of R372 and R374 does, we asked two questions. Are R372 and
R374 the preferred sites of autocitrullination? Also, what fraction
of PAD4 gets autocitrullinated? If only a small fraction of PAD4
is autocitrullinated, then this process should not impact the
activity of uncitrullinated enzyme.
To answer these questions, we took a quantitative proteomics
approach. PAD4 was autocitrullinated for various times and
digested with Glu-C and Lys-C to maximize peptide coverage.
The resulting peptides were then labeled with tandem mass tags
(TMTs) and were subjected to tandem mass analysis (Supple-
mentary Fig. 19). Enzyme incubated in the absence of calcium
was used as the negative control. From this analysis, we
identified 13 unique citrullination sites on PAD4 (Fig. 4a and
Supplementary Tables 1 and 5). Notably, these exclude the
previously reported R156, R205, R383, R609, and R639 and
include two new sites, R650 and R651. Although both R372 and
R374 residues show a time-dependent increase in citrullination,
citrullination of arginines 212/218, 484/488/495, and 650/651
occurs at a much higher rate. For example, the extent of
citrullination at arginines 212/218 and 484/488/495 is sig-
nificantly higher at 5 min than that at the 372 and 374 sites after
90 min (Fig. 4a, b). These observations indicate that arginines
372 and 374 are not the preferred sites of autocitrullination. In
addition, none of the observed autocitrullination sites exhibited
a marked decrease in the arginine-containing parent peptide
levels, which indicates that only a minor fraction of PAD4
undergoes autocitrullination, further explaining its nominal
impact on the enzyme activity. Nonetheless, these results
showcase how this technology provides the ability to system-
atically characterize the behavior of individual citrullinated
isoforms of any protein—both in vitro and in living cells—
providing a useful platform to understand the biology of this
PTM.
Discussion
Herein, we report the development of a genetic code expansion
(GCE) technique for the site-specific incorporation of Cit into
proteins in mammalian cells. Central to this technology is a
photocaged-Cit (SM60) and an EcLeuRS/tRNACUAEcLeu pair that
enables the incorporation of SM60 into proteins in response to a
TAG nonsense codon with high fidelity and efficiency. Subse-
quently, the photocage is removed with 365 nm light to generate
Cit. This technique overcomes several limitations of previous
methods used to incorporate Cit, including in vitro translation,
post-translational mutagenesis, and in vivo nonsense suppression
by chemically acylated tRNAs18,19,38. For example, chemically
acylated tRNAs are not readily synthesized, cannot be regener-
ated, and consequently give poor yields. By contrast, our
approach provides a highly scalable expression platform that can
be readily adapted by virtually any lab to site-specifically incor-
porate Cit into any mammalian protein, and thereby facilitate
cellular studies to understand the downstream implications of
this PTM.
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Specifically, we incorporated Cit at two known autocitrullina-
tion sites, R372 and R374, in PAD4. Kinetic studies indicate that
the R374Cit and R372Cit mutants are 9- and 181-fold less active
than WT PAD4. Detailed studies indicate that citrullination
induces local conformational changes within the active site that
leads to a slow reaction between C645 and the guanidium group
of the substrate, the first step in the catalytic cycle. While these
results indicate that citrullination of R372 and R374 would
decrease PAD4 activity, we found that autocitrullination does not
impact the enzymatic activity. Quantitative proteomics studies
indicate that 212/218 and 484/488/495, and not 372 and 374, are
the preferred sites of citrullination. While faster autocitrullination
of arginines 212/218 and 484/488/495 is likely due to their resi-
dence at the surface of PAD4, upon citrullination, they may
expose deeply buried autocitrullination sites by conformational
changes. Efforts are currently underway to elucidate the effect of
citrullination at these major sites, particularly the 484/488/495
residues because they are present at the interface of the head-to-
tail PAD4 dimer that is known to alter enzymatic activity.
Since it is well established that citrullination is critical for many
physiological processes, as well as in disease pathology, our
method will provide a direct and accessible approach to under-
stand the biology of this PTM at the molecular level. For example,
histone H3 citrullination at R26 leads to the transcriptional
activation of >200 genes in estrogen receptor-positive breast
cancer cells and inhibits the methylation of the neighboring K27
residue by 30,000-fold15. However, the mechanism of negative
crosstalk between these two PTMs remains poorly understood. In
Fig. 4 Autocitrullination sites in PAD4. a Heat map representing the time-dependent change in peptides containing arginine or citrulline at the indicated
positions (autocitrullination sites). Ca2+-untreated samples are negative controls. b Time-dependent autocitrullination at the major sites. R218 site could
not be shown because of disorder in that region (PDB: 1WDA)33. The increase in autocitrullination at these sites follows the same color code as in panel
(a).
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addition, we recently showed that SERPINs, nicotinamide N-
methyl transferase (NNMT), and pyruvate kinase isoform M2
(PKM2) are citrullinated in patients suffering from RA. Notably,
the citrullination of the SERPINs and NNMT dramatically
abolishes their enzymatic activity, while citrullinated PKM2
exhibits 2–3-fold higher activity than the WT enzyme14. How-
ever, the underlying reasons behind such biochemical phenom-
enon are unclear. Finally, citrullination has been reported to
impact NET formation, pluripotency, and efficient elongation by
RNA PolII, but, again, the underlying mechanisms remain
unclear1,8. With this GCE technology, it is possible to incorporate
Cit on demand and mechanistically address how this PTM
impacts these fundamental biological processes and pathways.
Methods
Materials and general methods. Nα-Fmoc-Nδ-L-ornithine hydrochloride, 2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 1-
hydroxybenzotriazole (HOBt), and other Fmoc-protected amino acids were pur-
chased from Chem-Impex International Inc. 1-(Isocyanatomenthyl)-2-nitro-
benzene (1M solution in toluene) was purchased from Ellanova Laboratories.
Triethylamine, trifluoroacetic acid, anhydrous dichloromethane, anhydrous
dimethylformamide, piperidine, and high-performance liquid chromatography
(HPLC)-grade acetonitrile were bought from Sigma-Aldrich. Halt protease inhi-
bitor cocktail (EDTA-free), Universal nuclease, Ni-NTA resin, Pierce™ Peptide
Desalting Spin Columns (catalog no. 89852), Pierce™ Quantitative Fluorometric
Peptide Assay kit (catalog No. 23290), and TMT10plex™ Isobaric Label Reagent
(catalog no. 90110) were obtained from Thermo Fisher Scientific. Deuterated
solvents were purchased from Cambridge Isotope Laboratories. Plasmid purifica-
tion kit was bought from Bio Basic Canada Inc. The TOP10 E. coli strain was used
for plasmid construction and propagation. The cells were grown in LB liquid
medium with 100 µg/mL ampicillin or 50 µg/mL kanamycin. Primers were syn-
thesized by Integrated DNA Technologies (Coralville, IA). Restriction enzymes
(NEB, Beverly, MA), Phusion Hot Start II DNA polymerase (Fisher Scientific,
MA), and T4 DNA ligase (Enzymatics, Beverly, MA) were used for plasmid con-
struction following the manufacturer’s protocols. White light and fluorescence
imaging of HEK293T cells expressing the EGFP-39-TAG reporter was performed
using a Zeiss AX10 microscope. Rabbit polyclonal anti-PAD4 (catalog no.
ab50332), rabbit polyclonal anti-histone H3 (Cit R2,8,17) (catalog no. ab5103), and
mouse monoclonal anti-histone H3 (catalog no. ab10799) were obtained from
Abcam and all these antibodies were used at 1:1000 dilution. EXPI293F cells,
EXPI293TM expression medium, and ExpiFectamineTM 293 Transfection Kit were
obtained from Gibco. Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine
serum, and antibiotic–antimycotic (100×) solution were obtained from Gibco and
were used for HEK293T (source: ATCC) cell maintenance. Mass spec grade Lys-C
(catalog no. VA117A) and sequencing grade Glu-C (catalog no. V165A) were
obtained from Promega. 1H and 13C NMR spectra were recorded in dimethyl
sulfoxide-d6 (DMSO-d6) as solvent using a Bruker 500MHz NMR spectrometer.
Chemical shift values are cited with respect to SiMe4 (TMS) as the internal stan-
dard. All the compounds were purified by reverse-phase HPLC using a semi-
preparative C18 column (Agilent, 21.2 mm × 250 mm, 10 µm) and a water/acet-
onitrile gradient supplemented with 0.05% trifluoroacetic acid. Fluorographs were
recorded using a Typhoon scanner with excitation/emission maxima of ∼546/579,
respectively. WT PAD4 obtained from a bacterial expression system (PAD4Bac) was
expressed and purified as reported earlier39.
Synthesis of SM60. SM60 (Fig. 1b) was synthesized as depicted in Supplementary
Fig. 21. Briefly, Fmoc-Orn-OH (1 g, 2.6 mmol) was suspended in anhydrous
dichloromethane and triethylamine (0.7 mL, 5.2 mmol) was added to it. 1-(Iso-
cyanatomenthyl)-2-nitrobenzene (1M solution in toluene) (2.6 mL, 2.6 mmol) was
then added dropwise and the reaction mixture was stirred at room temperature for
12 h. Excess triethylamine and dichloromethane was then evaporated under
reduced pressure to afford a yellowish-brown semisolid that was used for the
subsequent step without further purification. The crude product was dissolved in
1:4 piperidine/dimethylformamide (10 mL) and was stirred at room temperature
for 30 min. The reaction mixture was then vigorously stirred with excess hexane
and the hexane layer was decanted off. Washing with hexane was repeated several
times to remove most of the dimethylformamide. The pale yellow semisolid
obtained thereafter was purified by reverse-phase HPLC using a pre-packed C18
column and a water/acetonitrile (supplemented with 0.05% trifluoroacetic acid)
gradient as eluent to afford SM60 as a white solid (overall yield: 60%). SM60 was
thoroughly characterized with 1H and 13C NMR spectroscopy and MS. 1H NMR
(500MHz, DMSO-d6): δ 8.18 (s, 3H), 7.94 (dd, J= 9 Hz, 1H), 7.64–7.67 (m, 1H),
7.43–7.48 (m, 2H), 6.48 (t, J= 5 Hz, 1H), 6.24 (t, J= 5 Hz, 1H), 4.4 (d, J= 10 Hz,
2H), 3.85 (s, 1H), 2.93–2.97 (m, 2H), 1.61–1.75 (m, 2H), 1.40–1.49 (m, 1H),
1.31–1.39 (m, 1H); 13C NMR (500MHz, DMSO-d6): δ 171.5, 158.5, 148.3, 136.6,
134.2, 130.0, 128.4, 124.9, 52.3, 40.7, 39.1, 28.0, 26.2; HRMS (m/z): [M+H]+ calcd.
for C13H18N4O5: 311.1355; found, 311.1337.
Synthesis of SM70. SM70 (Fig. 1b) was synthesized using an automated solid-
phase peptide synthesizer (PS3, Protein Technologies, Inc.) by following the
manufacturer’s protocol. Briefly, Fmoc-Lys(Boc)-Wang resin (350 mg, 0.2 mmol)
was taken in a 30 mL glass reaction vessel, and Fmoc-SM60 (425 mg, 0.8 mmol),
Fmoc-Ala-OH (249 mg, 0.8 mmol), Fmoc-Ser(tBu)-OH (306 mg, 0.8 mmol),
Fmoc-Asp(OtBu)-OH (329 mg, 0.8 mmol), Fmoc-Phe-OH (310 mg, 0.8 mmol),
Fmoc-Val-OH (272 mg, 0.8 mmol), Fmoc-Val-OH (272 mg, 0.8 mmol), Fmoc-Trp
(Boc)-OH (421 mg, 0.8 mmol), Fmoc-Leu-OH (283 mg, 0.8 mmol), and Fmoc-Thr-
OH (318 mg, 0.8 mmol) were taken in separate amino acid vials. HBTU (303 mg,
0.8 mmol) and HOBt (108 mg, 0.8 mmol) were then added to each amino acid vial.
N-methylmorpholine (0.4 M in N,N-dimethylformamide (DMF)) was used as a
base for the activation of the carboxylic acid group with HBTU and HOBt. The N-
terminal Fmoc protecting group on each amino acid was removed with 20%
piperidine in DMF. Each peptide coupling reaction was carried out for 1 h. Once all
the amino acids were coupled, the resin was transferred to a synthetic column,
thoroughly washed with DMF and dichloromethane (DCM), and the peptide was
cleaved from the resin by treating with a cleavage cocktail (95% trifluoroacetic acid,
4.5% triisopropylsilane, 0.5% water, 10 mL) at room temperature for 30 min with
constant mixing. The flow-through was collected and the resin was washed 2–3
times with trifluoroacetic acid. The combined flow-through and trifluoroacetic acid
washes were then treated with 8–10 times excess cold diethyl ether to precipitate
the peptide. Excess ether and trifluoroacetic acid was slowly evaporated by purging
nitrogen. The crude peptide was purified by reverse-phase HPLC using a pre-
packed C18 column and a water/acetonitrile (supplemented with 0.05% tri-
fluoroacetic acid) gradient to afford SM70 as a white solid (overall yield: 15%).
SM70 was characterized by electrospray ionization (ESI) MS, HRMS (m/z) cal-
culated for C69H100N16O19 [M+ 2H]2+: 729.3753, found 729.3730.
Construction of plasmids. The previously reported pAcBac3-EcLeuTAG-EGFP-
39-TAG plasmid was used to construct additional plasmids31. The EGFP-39-TAG
reporter in this plasmid was replaced with WT PAD4 gene using flanking SfiI
restriction site to create pAcBac3-EcLeuPLRS1TAG-PAD4WT. For incorporation
of o-nitrobenzyl-Cit, TAG codons were introduced at desired sites by site-directed
mutagenesis using overlap-extension polymerase chain reaction. For the R372TAG
mutation, PAD4WT-forward+ PAD4 R372TAG inner reverse primer and PAD4
R372TAG inner forward primer+ PAD4WT-Reverse was used to create mutated
5ʹ and 3ʹ fragments of PAD4 (for primer sequences see Supplementary Table 6).
The full-length PAD4 R372TAG insert was generated by the overlap extension of
these fragments. The pAcBac3-EcLeuPLRS1TAG-PAD4 R374TAG was con-
structed similarly using the PAD4 R374TAG inner forward primer and PAD4
R374TAG inner reverse primer. The open-reading frame for eRF1-E55D35 was
purchased from Integrated DNA Technologies as a gBlock. The gBlock was
amplified with eRF1-forward and eRF1-reverse primers (Supplementary Table 6)
and was introduced into pIDTSMART vector with flanking NheI and XhoI
restriction sites to create pIDTSMART eRF1-E55D.
EGFP and PAD4 expression from HEK293T cells. HEK293T cells were main-
tained at 37 °C in a humidified incubator supplemented with 5% CO2. Cells were
seeded at 9 × 106 cells per 10 cm plate 24 h before transfection. EGFP and WT
PAD4 transfections were performed by incubating 10 µg plasmid DNA, 50 µL
polyethylenimine (PEI) (1 mg/mL; Polysciences, Warrington, PA), and 180 µL
DMEM for 10 min at room temperature, followed by adding the solution dropwise
to the culture medium of the cells. For EGFP-39-TAG expression, 1 mM SM60 was
added to the culture medium following transfection. For SM60 incorporation into
PAD4 at positions 372 and 374, 12 µg of PAD4 R372TAG or PAD4 R374TAG and
8 µg of pIDTSMART eRF1-E55D plasmids were incubated with a mixture of 100
µL PEI and 180 µL DMEM for 10 min at room temperature before adding to cells.
SM60 was added at the same time to a final concentration of 1 mM, and 2 mM
sodium butyrate was added to enhance protein expression. The full gels for the
EGFP and PAD4 expression are given in Supplementary Figs. 7 and 20b.
EGFP fluorescence analysis. EGFP fluorescence was analyzed 48 h after trans-
fection. DMEM was exchanged with PBS and the plates were irradiated at 365 nm
(120W, 10 cm × 10 cm LED array; Larson Electronics) for 75 s at 4 °C to decage
SM60. Cells were then harvested and resuspended in 600 µL CelLytic M buffer
(Sigma, St. Louis, MO) with Halt Protease inhibitor Cocktail (Thermo Scientific,
Waltham, MA) and Pierce Universal Nuclease for Cell Lysis (Fisher Scientific,
Hampton, NH). Lysates were clarified by centrifugation at 16,000 × g for 10 min
and 100 µL of supernatant was transferred to a clear-bottom 96-well plate for
fluorescence measurement. Fluorescence was measured using a Zeiss AX10
microscope (Ex. 488 nm; Em. 534 nm). All the experiments were performed at least
in duplicate.
LC-MS analysis of EGFP. LC/MS analyses of the purified EGFP were performed
on Agilent Technologies 6230 TOF LC/MS with Aerns 3.6 µm WIDEEPORE XB-
C8 20 LC column 100 × 4.6 mm2.
Cytotoxicity of SM60 in HEK293T cells. HEK293T cells were seeded (2 × 104
cells/well) on a 96-well plate and grown in DMEM (supplemented with 10% heat-
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inactivated fetal bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin) for
48 h. Cells were then treated with DMSO (for control) or various concentrations of
SM60. In a separate experiment, cells were briefly (3 min) irradiated with 365 nm
UV following SM60 treatment and were allowed to grow at 37 °C for 48 h. Cell
viability was measured using CellTiter-Blue® (Promega) by following the manu-
facturer’s protocol. Equation (1),
Y ¼ Bottomþ Top Bottomð Þ=½1þ 10 log EC50Xð Þ ´Hillslopeð Þ; ð1Þ
was used to fit a ten-point dose–response curve to determine the EC50 values for
inhibition of cell proliferation using GraphPad Prism 8.0. Top and Bottom are
plateaus of the dose–response curve, X is the log of SM60 concentration, Hillslope
is the slope factor or Hill slope. All the experiments were performed in triplicate.
Overexpression of WT and mutant (R374Cit) PAD4 in EXPI293F cells.
EXPI293F cells were co-transfected with the engineered LeuRS/tRNALeu/PAD4 and
eRF1 genes using ExpiFectamineTM 293 transfection kit by following the manu-
facturer’s protocol. Briefly, EXPI293F cells were grown to 2.9 × 106 density in the
EXPI293TM expression medium (9 mL) at 37 °C under 5% CO2 atmosphere. pAc-
Bac3 plasmid (6 µg) encoding the genetically engineered LeuRS, tRNALeu, and WT
PAD4 or mutant PAD4 (containing TAG mutation at the 374 position) and the
plasmid encoding release factor, pIDTSMART eRF1-E55D (4 µg), were resuspended
in 0.5mL opti-MEMTM I reduced serum media. ExpiFectamineTM (27 µL) was also
resuspended in 0.5mL opti-MEMTM media and then the plasmid mixture was
slowly added to ExpiFectamineTM solution. This mixture was incubated at room
temperature for 20min to form the DNA polyplex. Then the DNA polyplex (1 mL)
was slowly transferred to the EXPI293F cell suspension (9mL) and SM60 (100 µL of
100mM stock in DMSO, 1 mM final) was added to the medium. The cells were then
incubated at 37 °C under 5% CO2 atmosphere for 24 h with constant shaking.
Transfection enhancers 1 (50 µL) and 2 (500 µL) (supplied with the ExpiFectami-
neTM 293 transfection kit) were then added to the cell suspension and the cells were
further grown at 37 °C under 5% CO2 atmosphere for 48 h with constant shaking.
Cells were then harvested, washed with cold Dulbecco’s phosphate-buffered
saline (DPBS), resuspended in 5 mL DPBS, and were taken in a cell culture dish
(100mm× 20mm, Corning). Cells were then irradiated with 365 nm light for 5 min
using a photoreactor (Luzchem) containing 14 UV-A lamps (8W each). After
UV-A irradiation, cells were harvested, resuspended in 1mL in DPBS (containing
1× Halt protease inhibitor cocktail), and lysed using a probe sonicator. Over-
expression of WT and mutant PAD4 was confirmed by western blot analysis of the
EXPI293F cell lysate using rabbit polyclonal anti-PAD4 antibody.
Purification of WT and mutant PAD4 from HEK293T cells. Cells from a 10 cm
plate were harvested 48 h after transfection. For cells that overexpressed proteins
containing SM60, media were exchanged with PBS and the plates were irradiated at
365 nm (120W, 10 cm × 10 cm LED array (Larson Electronics)) for 75 s at 4 °C to
decage SM60 right before harvesting. The cells were resuspended in 600 µL Cel-
Lytic M buffer (Sigma, St. Louis, MO) with Halt protease inhibitor cocktail
(Thermo Scientific, Waltham, MA) and Pierce universal nuclease for cell lysis
(Fisher Scientific, Hampton, NH). After a 10-min incubation at room temperature,
1.2 mL of equilibration buffer (20 mM Na2HPO4, 300 mM NaCl, 10 mM imidazole
pH 7.4) was added. Lysate was clarified by centrifugation at 16,000 × g for 10 min at
4 °C. The clarified cell-free extract was subjected to Ni-NTA affinity chromato-
graphy using HisPur resin (Fisher Scientific, Hampton, NH) following the man-
ufacturer’s protocol.
Purification of WT and mutant PAD4 from EXPI293F cells. Following UV-A
irradiation, cells were resuspended in lysis buffer (20 mM Tris-HCl pH 8.0, 400
mM NaCl, 10 mM imidazole, 2 mM DTT, 10% glycerol, 1× protease inhibitor
cocktail, 1× universal nuclease) and lysed using a probe sonicator. The lysate was
centrifuged at 18,000 × g for 20 min at 4 °C and the supernatant was incubated with
Ni-NTA agarose beads (prewashed with the lysis buffer) for 30 min at 4 °C on an
end-over-end shaker. The beads were then transferred to a synthetic column and
washed sequentially with buffer 1 (20 mM Tris-HCl pH 8.0, 400 mM NaCl, 50 mM
imidazole, 2 mM DTT, 10% glycerol) and buffer 2 (20 mM Tris-HCl, pH 8.0, 400
mM NaCl, 75 mM imidazole, 2 mM DTT, 10% glycerol). Finally, PAD4 was eluted
from the beads using elution buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 300
mM imidazole, 2 mM DTT, 10% glycerol). Eluted PAD4 was then dialyzed against
20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 2 mM DTT, 10% glycerol using a dialysis
cassette with a molecular weight cutoff of 3.5 kDa.
Digestion of the PAD4R372Cit and PAD4R374Cit mutants, and LC-MS/MS
analysis. The R372Cit and R374Cit mutants (15 µg) were independently resus-
pended in 20 mM Tris-HCl (200 µL, pH 7.4) and then trichloroacetic acid (20%
final) added to the samples. The resultant cloudy mixture was vortexed vigorously
and was kept at −20 °C for 30 min to precipitate the protein. Then, the mixture was
centrifuged at 21,000 × g for 30 min at 4 °C. The pellet was washed with cold
acetone, resuspended in 30 µL of 8 M urea in PBS (pH 7.4) with sonication, and 70
µL of 100 mM ammonium bicarbonate was added to the solution. Then, 1.5 µL of
1M DTT was added and the solution was incubated at 65 °C for 20 min. A measure
of 2.5 µL of freshly prepared 500 mM iodoacetamide was added and the solution
was incubated at room temperature for 30 min in dark. The alkylation reaction was
diluted by the addition of 120 µL PBS (pH 7.4). Lys-C (1 µL of a 1 µg/µL solution,
reconstituted in water) and Glu-C (2 µL of a 0.5 µg/µL solution, reconstituted in
water) was then added to the samples and the mixture was incubated at 37 °C for
16 h. The proteolysis reaction was terminated by adding 10 µL of formic acid. The
peptide mixture was then desalted using PierceTM desalting C18 spin columns
following the manufacturer’s protocol and the samples were analyzed by LC-MS/
MS as described below.
Cytotoxicity of PAD4 expression in HEK293T cells. HEK293T cells were seeded
(2 × 104 cells/well) on 96-well plate and were allowed to grow in DMEM (sup-
plemented with 10% heat-inactivated fetal bovine serum, 100 units/mL penicillin,
100 µg/mL streptomycin) for 48 h. Cells were then transfected with appropriate
plasmids (120 ng PAD4 plasmid and 80 ng pIDTSMART eRF1-E55D for each well)
using Lipofectamine 2000 (500 ng for each well) in Opti-MEM medium (Gibco).
After 5 h, the medium was changed to DMEM and DMSO (for WT PAD4) or
SM60 (0.25, 5, and 1 mM for R374Cit PAD4) was added. Cells were then allowed
to grow at 37 °C for 48 h. Cell viability was measured before and after photo-
decaging (by UV treatment for 3 min) using CellTiter-Blue® (Promega) by fol-
lowing the manufacturer’s protocol. Untransfected cells served as the control. All
the experiments were performed in triplicate.
Time-dependent Cit production. PAD4 (6 µL of a 1 µM stock, 100 nM final) was
added to a pre-warmed (10 min, 37 °C) reaction mixture (60 µL final) containing
BAEE (10 mM), CaCl2 (10 mM), Tris-HCl (100 mM, pH 7.4), NaCl (50 mM), and
DTT (2 mM). This mixture was incubated at 37 °C for 0, 30, 50, and 90 min, after
which the reaction was stopped by flash freezing with liquid nitrogen. The pro-
duction of Cit at various time points was quantitated by the standard COLDER
assay40,41. The time-dependent production of Cit by PAD4 was fit to the equation
for a straight line using GraphPad Prism 8.0. All the reactions were performed at
least in duplicate.
Michaelis–Menten kinetics of WT and mutant PAD4. PAD4 (50 nM final for
WT, 75 nM final for R372Cit, or 100 nM final for R374Cit) was added to a pre-
warmed (10min, 37 °C) reaction mixture (60 µL final) containing various con-
centrations of BAEE (0, 0.5, 1, 2.5, 5, and 10mM), CaCl2 (10mM), Tris-HCl
(100mM, pH 7.4), NaCl (50mM), and DTT (2mM). This mixture was incubated at
37 °C for 45min (for WT), 90min (for R374Cit), and 120min (for R372Cit), followed
by quenching with liquid nitrogen. The rate of Cit formation at various BAEE con-
centrations was quantified with the COLDER assay40,41. The rates were plotted
against the BAEE concentration and were fit to the Michaelis–Menten equation using
GraphPad Prism 8.0. All the reactions were performed at least in duplicate.
Calcium dependence of WT PAD4. PAD4Bac (purified from bacterial expression
system) and PAD4Mam (purified from mammalian expression system) (6 µL of 0.5
µM stock, 50 nM final) were added to separate pre-warmed (10 min, 37 °C) reac-
tion mixtures (60 µL final) containing BAEE (10 mM), various concentrations of
CaCl2 (0, 0.25, 0.5, 1, 2.5, 5, and 10 mM), Tris-HCl (100 mM, pH 7.4), NaCl (50
mM, and DTT (2 mM). This mixture was incubated at 37 °C for 45 min, followed
by flash freezing with liquid nitrogen. The production of Cit at various con-
centrations of CaCl2 by PAD4 was quantified with the COLDER assay40,41. The
calcium dependence of Cit production by PAD4 was fit to Eq. (2),
v ¼ Vmax * Ca2þ
 h
= Kh0:5þ Ca2þ
 h  ð2Þ
using GraphPad Prism 8.0, where v is the velocity of the reaction, Vmax is the
maximum velocity of the reaction, [Ca2+] is the concentration of calcium, h is the
hill slope, and K0.5 is the calcium concentration that gives half-maximal velocity.
All the reactions were performed at least in duplicate.
Effect of autocitrullination of WT PAD4 on the enzymatic activity. PAD4Bac
(0.5 µM final) was added to a pre-warmed (10 min, 37 °C) solution containing
CaCl2 (0 or 10 mM), Tris-HCl (100 mM, pH 7.4), NaCl (500 mM), and DTT (2
mM). At various time points (0, 5, 15, 30, 60, and 90 min), 6 µL of this reaction
mixture was removed and was added to a pre-warmed (10 min, 37 °C) reaction
mixture (10 mM BAEE, 10 mM CaCl2, 100 mM Tris, pH 7.4, 500 mM NaCl, 2 mM
DTT, with a final volume of 60 µL). After 45 min, the reaction mixture was flash
frozen with liquid nitrogen. The production of Cit at various time points was
quantified with the COLDER assay40,41. The loss in activity of PAD4 over time was
fit into single exponential decay using GraphPad Prism 8.0. All the reactions were
performed at least in duplicate.
Rh-PG labeling of autocitrullinated PAD4. Rh-PG labeling of autocitrullinated
PAD4 was performed as reported earlier with minor modifications13. PAD4 (0.5
µM final) was added to a pre-warmed (10 min, 37 °C) reaction mixture containing
CaCl2 (0 or 10 mM), Tris-HCl (100 mM, pH 7.4), NaCl (500 mM), and DTT (2
mM). At various time points (0, 5, 15, 30, 60, and 90 min), the reaction was stopped
by flash freezing in liquid nitrogen. The samples were thawed, and trichloroacetic
acid (20% final) and Rh-PG (80 µM final) were sequentially added to it. The
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reaction mixture was incubated at 37 °C for 1 h. Then, the reaction was quenched
with Cit (100 mM final) dissolved in 50 mM Tris-HCl (pH 7.4) and the mixture
was further incubated at 37 °C for 30 min. The samples were placed at −20 °C for
30 min and the precipitated proteins were collected by centrifugation (21,000 × g
for 30 min) at 4 °C. The protein pellet was washed with cold acetone and dried.
Then, the pellet was dissolved in 40 µL buffer containing 100 mM arginine, 20 mM
Tris-HCl (pH 7.4), 1% sodium dodecyl sulfate (SDS), and 10 µL 5× SDS loading
dye. The proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and the fluorescently labeled bands were visualized by scanning the gel in a
typhoon scanner (excitation and emission maxima ~546 and 579 nm, respectively).
The fluorescent intensities of protein bands were quantified using ImageJ 1.52v and
were normalized against the coomassie intensities that indicate the amount of
protein present in each lane. All the reactions were performed at least in duplicate.
The full gel for the Rh-PG labeling of autocitrullinated PAD4 is given in Supple-
mentary Fig. 20a.
RFA labeling of WT and R374Cit PAD4. RFA labeling of PAD4 was carried out
by following a protocol similar to that established for PAD1 and PAD210,11. Briefly,
PAD4 (100 nM final) was added to pre-warmed (10 min, 37 °C) reaction mixture
(100 mM Tris pH 7.4, 500 mM NaCl, 0 or 10 mM CaCl2, and 2 mM DTT in a final
volume of 30 µL) containing RFA (200 nM final). After incubating at 37 °C for 2 h,
the reaction mixture was quenched with 5× SDS-PAGE loading dye and boiled at
95 °C for 10 min. The proteins were separated by SDS-PAGE using a 4–20%
gradient gel and fluorescently labeled proteins were visualized by scanning the gel
in a typhoon scanner (excitation and emission maxima ~546 and 579 nm,
respectively). The fluorescent intensities of protein bands were quantified using
ImageJ 1.52v. All the reactions were performed at least in duplicate.
RFA labeling of WT and R374Cit PAD4 in EXPI293F lysate. RFA (10 µM) was
added to a pre-warmed (10 min, 37 °C) reaction mixture (2 mg/mL EXPI293F
lysate containing WT or R374Cit or R372Cit PAD4 in 1× PBS, 2 mM CaCl2, and
2 mM DTT in a final volume of 50 µL) and the mixture was incubated at 37 °C for
2 h. The reaction was quenched with 5× SDS-PAGE loading dye and was boiled at
95 °C for 10 min. The proteins were separated on a 4–20% SDS-PAGE gel and the
fluorescently labeled proteins were visualized by scanning the gel in a typhoon
scanner (excitation and emission maxima ~546 and 579 nm, respectively). The
fluorescent intensities of protein bands were quantified using ImageJ 1.52v. All the
reactions were performed at least in duplicate.
Histone H3 citrullination in live HEK293T cells. HEK293T cells were seeded
(4 × 105 cells/well) on 6-well plates and were allowed to grow in DMEM (sup-
plemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin, 100
µg/mL streptomycin) for 48 h. Cells were then transfected with appropriate plas-
mids (3 µg PAD4 plasmid and 2 µg pIDTSMART eRF1-E55D for each well) using
Lipofectamine 2000 (12.5 µg for each well) in Opti-MEM medium (Gibco). After 5
h, the medium was changed to DMEM and DMSO (for WT PAD4) or SM60 (1
mM for R374Cit PAD4) was added. Cells were then allowed to grow at 37 °C for
48 h. Cells were washed with serum-free DMEM (supplemented with 100 U/mL
penicillin, 100 µg/mL streptomycin), resuspended in the same medium, and were
irradiated with 365 nm UV for 3 min. Then, the cells were treated with CaCl2 (1
mM) and a combination of CaCl2 (1 mM) and ionomycin (5 µM) for 3 h at 37 °C.
After this, cells were lysed and the lysates were analyzed by Western blotting using
anti-histone H3 Cit (R2,8,17) and anti-histone H3 primary antibodies. PAD4
expression was quantified by using an anti-PAD4 primary antibody. Band inten-
sities for citrullinated histone H3 were normalized against those for histone H3 and
PAD4 using the following algorithm:
Normalized histoneH3Cit ¼ H3Cit= H3 ´PAD4ð Þ½  ´ 106: ð3Þ
All the experiments were performed in triplicate. The full gels for the histone H3
citrullination by WT and R374Cit PAD4 are given in Supplementary Fig. 20c.
Thermal shift assay. A 50 µL reaction mixture (EXPI293F lysate containing
overexpressed WT PAD4 (1.5 mg/mL) or R374Cit mutant (2 mg/mL), 1× PBS and
DMSO (1% final)) was heated at various temperatures (25, 40, 50, 60, 65, 70, 75, 85
and 90 °C) for 5 min, followed by flash freezing with liquid nitrogen. The samples
were thawed and the precipitated proteins were separated by centrifugation
(21,000 × g, 30 min) at 4 °C. Forty microliters of the supernatant was mixed with
10 µL of 5× SDS-PAGE loading dye and the mixture was boiled at 95 °C for 10 min.
The proteins were separated by SDS-PAGE using a 4–20% gradient gel and the
soluble fractions of PAD4 were quantitated by western blot analysis using a rabbit
polyclonal anti-PAD4 antibody. This assay was also performed separately in the
presence of CaCl2 (1 mM final) and a PAD4-selective ligand, GSK199 (10 µM
final). For these assays, the reaction mixture was incubated with CaCl2 or GSK199
at room temperature for 5 min before heating up at different temperatures. All the
reactions were performed at least in duplicate.
Proteomics study on autocitrullinated PAD4. Fifty micrograms of PAD4 was
incubated at 37 °C for various times (0, 5, 15, 30, and 90 min) in the absence and
presence (10 mM) of CaCl2, followed by flash freezing with liquid nitrogen. The
samples were thawed and trichloroacetic acid (20% final) was added. Then, the
samples were placed at −20 °C for 30 min and the precipitated proteins were
collected by centrifugation (21,000 × g, 30 min) at 4 °C, washed with cold acet-
one, and dried. The protein pellet was resuspended in 6 M urea (100 µL) in PBS
and TCEP (tris(2-carboxyethyl)phosphine) (2 mM final) was added to it. The
solution was incubated at 37 °C for 1 h. Then iodoacetamide (4 mM final) was
added and the solution was incubated at 37 °C for 30 min in dark. Then, 200 µL
of PBS was added to the solution to achieve a final concentration of urea of 2 M.
Lys-C (1 µL of a 1 µg/µL solution, reconstituted in water) and Glu-C (2 µL of a
0.5 µg/µL solution, reconstituted in water) were then added to the samples and
then incubated at 37 °C for 16 h. The proteolysis reaction was terminated by
adding 15 µL of formic acid. The peptide mixture was then desalted with Pier-
ceTM desalting C18 spin columns, resuspended in 120 µL of HEPES buffer (100
mM, pH 8.5), and the total peptide content in each sample was quantified and
normalized using the PierceTM Quantitative Fluorometric Peptide Assay kit,
according to the manufacturer’s protocol. Eight microliters of a 19.5 µg/µL
acetonitrile stock of TMT10plexTM isobaric labeling reagents (TMT10-126,
TMT10-127N, TMT10-127C, TMT10-128N, TMT10-128C, TMT10-129N,
TMT10-129C, TMT10-130N, TMT10-130C, and TMT10-131) were added to
100 µL samples treated in the absence and presence of calcium for five different
time points (0, 5, 15, 30, and 90 min). The reaction mixtures were incubated at
room temperature for 1 h. To quench the reaction, 8 µL of 5% hydroxylamine
was added to each sample and the mixture was incubated at room temperature
for 15 min. Then, the ten samples (0, 5, 15, 30, and 90 min samples in the
absence and presence of calcium) were combined together in a new micro-
centrifuge tube and desalted using C18 spin columns. This experiment was
performed in triplicate.
LC-MS/MS analysis. Peptides were lyophilized, resuspended in 5% acetonitrile,
0.1% (v/v) formic acid in water, and loaded at 4.0 µL/min by a NanoAcquity UPLC
(Waters Corporation, Milford, MA) onto a 100 µm I.D. fused-silica pre-column
packed with 2 cm of 5 µm (200 Å) Magic C18AQ (Bruker-Michrom), equilibrated
with 5% acetonitrile, 0.1% (v/v) formic acid in water. After trapping for 4.0 min on
the pre-column, peptides were eluted at 300 nL/min from a 75 µm I.D. gravity-
pulled analytical column packed with 25 cm of 3 µm (100 Å) Magic C18AQ par-
ticles using a gradient of mobile phase A, 0.1% (v/v) formic acid in water and
mobile phase B, 0.1% (v/v) formic acid in acetonitrile as follows: 0–100 min (5–35
%B), 100–120 min (35–65%B), 120–121 min (65–95 %B), and 121–126 min (95%
B). Ions were introduced by positive ESI via liquid junction at 1.4 kV into a Q
Exactive hybrid quadrapole orbitrap mass spectrometer (Thermo Scientific, Wal-
tham, MA). Mass spectra were acquired over m/z 300–1750 at 70,000 resolution
(m/z 200) with an AGC target of 1e6, and data-dependent acquisition selected the
top 10 most abundant precursor ions for tandem MS by higher energy collisional
dissociation fragmentation using an isolation width of 1.6 Da, max fill time of 100
ms, and AGC target of 1e5. Peptides were fragmented by a normalized collisional
energy (NCE) of 27 and product ion spectra acquired at a resolution of 17,500 (m/z
200). For TMT-labeled samples, NCE was set to 32 and product ion spectra were
acquired at a resolution of 35,000 (m/z 200).
LC-MS/MS data analysis. Raw data files were peak processed with Proteome
Discoverer (version 2.1, Thermo Scientific, Waltham, MA), followed by identifi-
cation using Mascot Server (version 2.5, Matrix Science) against the Swissprot
human or E. coli (TMT-labeled samples) FASTA file. Proteolytic enzyme was set to
Lys-C and Glu-C with two missed cleavages. Variable modifications of N-terminal
acetylation, oxidized methionine, pyroglutamic acid for glutamine, deamidation of
asparagine, and citrullination of arginine were implemented. Carbamidomethyla-
tion of cysteines and TMT10-plex modification at lysine and peptide N terminus
were set as fixed modifications. Assignments were made using a 10 p.p.m. mass
tolerance for the precursor and 0.05 Da mass tolerance for the fragments. All non-
filtered search results were processed by Scaffold (version 4.10.0, Proteome Soft-
ware, Inc.) utilizing the Trans-Proteomic Pipeline (Institute for Systems Biology)
with threshold values set at 90% for peptides (1% false-discovery rate) and 99% for
proteins (two peptides minimum, 6% false-discovery rate). TMT product ion ratios
were calculated using the Scaffold Q+ S analysis software.
Statistics and reproducibility. Experiments corresponding to Figs. 2a, c and 3b, c
and Supplementary Fig. 7 were independently repeated three times with similar
results. Experiments corresponding to Figs. 2d and 3a and Supplementary Figs. 3–
6, 8–9, 14, 16b, c, 17a–f, and 18 were independently repeated two times with similar
results.
Biological materials. All the plasmids are available upon request to the corre-
sponding authors (P.R.T. and A.C.) by email.
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All the raw data are available upon request to the corresponding authors (P.R.T. and
A.C.) by email. Source data are provided with this paper.
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